SCHEMBL2071252

SCHEMBL2071252

CCCCCCCCC(O)COCC(CO)OCCCC

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.53
HTT P42858 1/20 0.44
CNR2 P34972 3/20 0.43
ALDH1A1 P00352 1/20 0.43
CNR1 P21554 1/20 0.43
LPAR1 Q92633 4/20 0.41
LPAR3 Q9UBY5 4/20 0.41
LPAR2 Q9HBW0 1/20 0.41
LMNA P02545 1/20 0.40
DNM1 Q05193 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
PLA2G2C Q5R387 1/20 0.39
LPAR5 Q9H1C0 1/20 0.39
PLA2G2A P14555 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9813378 0.87 USP2 (0.67) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL11728648 0.87 USP2 (0.62) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL2840856 0.87 USP2 (0.71) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL3325348 0.87 USP2 (0.71) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL2345876 0.87 USP2 (0.71) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL2354120 0.87 USP2 (0.71) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL2347220 0.87 USP2 (0.71) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL2348818 0.86 USP2 (0.59) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL702717 0.86 USP2 (0.65) USP2HTTCNR2ALDH1A1CNR1
SCHEMBL9813387 0.85 USP2 (0.69) USP2HTTCNR2ALDH1A1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163939-B2 Ascorbic acid derivative or salt thereof, production method thereof, and cosmetic Seikwa Kasei Company, Limited (JP) 2012-04-24 US disclosed
US-20110059034-A1 ASCORBIC ACID DERIVATIVE OR SALT THEREOF, PRODUCTION METHOD THEREOF, AND COSMETIC SEIWA KASEI COMPANY, LIMITED (JP) 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059034-A1 ASCORBIC ACID DERIVATIVE OR SALT THEREOF, PRODUCTION METHOD THEREOF, AND COSMETIC CYP2R1, CYP24A1, RARA USP2 2360/4885HTT 1304/4885CNR2 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.